GO
| HSI1 | 23,637.60 | -370.95 | 195.86B |
| HSCEI1 | 7,937.53 | -119.23 | 71.74B |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-12 14:56:20 Goldman Sachs published a research report saying that China's CRO and CDMO companies delivered solid results in the third quarter. Despite continued negative impact from foreign exchange factors, momentum in new orders remained strong, coupled with accelerated capacity expansion, which is expected to provide greater visibility for manufacturing businesses next year. Improved biotech financing, M&A and business development activities, as well as emerging AI-driven drug discovery activities, also supported rising demand for wet labs. The broker noted that WUXI APPTEC (02359.HK)'s new orders in the first three quarters of this year accelerated to about 60% YoY, while PHARMARON (03759.HK) recorded around 30% growth in the third quarter, TIGERMED (03347.HK) posted growth close to 30%, and ASYMCHEM (06821.HK) also maintained around 30% growth. Updated guidance was broadly in line with the broker's expectations. Among them, WUXI APPTEC (02359.HK) raised its 2026 continuing operations revenue growth guidance to 40% to 42%, while its capital expenditure budget continued to advance. Following the recent pullback in share prices of China's CRO and CDMO sector, Goldman Sachs believed the weakness instead created better positioning opportunities. WUXI APPTEC (02359.HK) being removed from the US Department of Defense's 1260H list reduced the risk of being included in the preliminary BCC list through that route. The broker believed short-term risks related to the Biosecure Act had eased, although geopolitical developments could still bring volatility to share prices.(gc/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |